MRONJ risk of adjuvant bisphosphonates in early stage breast cancer

被引：15

作者：

Patel, V. ^{[1
]}

Mansi, J. ^{[2
]}

Ghosh, S. ^{[2
]}

Kwok, J. ^{[1
]}

Burke, M. ^{[3
]}

Reilly, D. ^{[3
]}

Nizarali, N. ^{[3
]}

Sproat, C. ^{[1
]}

Chia, K. ^{[2
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, Dept Oral Surg, Fl 23,Tower Wing, London SE1 9RT, England

[2] Guys & St Thomas NHS Fdn Trust, Dept Oncol, Fl 23,Tower Wing, London SE1 9RT, England

[3] Guys & St Thomas NHS Fdn Trust, Sedat & Special Care, Fl 23,Tower Wing, London SE1 9RT, England

来源：

BRITISH DENTAL JOURNAL | 2018年 / 224卷 / 02期

关键词：

ZOLEDRONIC ACID; PREVENTIVE MEASURES; OSTEONECROSIS; JAW; IMPLEMENTATION; MANAGEMENT; REDUCE;

D O I：

10.1038/sj.bdj.2017.1039

中图分类号：

R78 [口腔科学];

学科分类号：

1003 ;

摘要：

Medication-related osteonecrosis of the jaw (MRONJ) has most commonly been associated with bisphosphonates. The routine uses of these drugs are now well established predominantly in metastatic cancer with bone involvement, multiple myeloma, hypercalcaemia, osteoporosis and Paget's disease. Recently, however, the use of bisphosphonates in early breast cancer has shown a reduction in breast cancer recurrence and breast cancer deaths. This new indication for their use approximates to a further 20,000 women per year in the UK being prescribed bisphosphonates. In this article, we consider the dental impact of this new use of bisphosphonates, report on the rates of MRONJ seen in early breast cancer bisphosphonate trials and discuss strategies aimed at minimising the risk of bisphosphonate-exposed patients developing MRONJ.

引用

页码：74 / 79

页数：6

共 50 条

[41] The role of bisphosphonates as adjuvant therapy for breast cancer.
Gralow J.R.
Current Oncology Reports, 2001, 3 (6) : 506 - 515
[42] Bisphosphonates: ready for use as adjuvant therapy of breast cancer?
Theriault, Richard L.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2010, 22 (01) : 61 - 66
[43] The role of bisphosphonates in early breast cancer
Paterson, Alexander H. G.
ONCOLOGIST, 2006, 11 : 13 - 19
[44] Use of Bisphosphonates and Risk of Breast Cancer
Peter Vestergaard
Lone Fischer
Marco Mele
Leif Mosekilde
Peer Christiansen
Calcified Tissue International, 2011, 88 : 255 - 262
[45] Use of Bisphosphonates and Risk of Breast Cancer
Vestergaard, Peter
Fischer, Lone
Mele, Marco
Mosekilde, Leif
Christiansen, Peer
CALCIFIED TISSUE INTERNATIONAL, 2011, 88 (04) : 255 - 262
[46] Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
Hadji, P.
Coleman, R. E.
Wilson, C.
Powles, T. J.
Clezardin, P.
Aapro, M.
Costa, L.
Body, J. -J.
Markopoulos, C.
Santini, D.
Diel, I.
Di Leo, A.
Cameron, D.
Dodwell, D.
Smith, I.
Gnant, M.
Gray, R.
Harbeck, N.
Thurlimann, B.
Untch, M.
Cortes, J.
Martin, M.
Albert, U. -S.
Conte, P. -F.
Ejlertsen, B.
Bergh, J.
Kaufmann, M.
Holen, I.
ANNALS OF ONCOLOGY, 2016, 27 (03) : 379 - 390
[47] THE RISK OF ISCHEMIC HEART DISEASE WITH ADJUVANT ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY STAGE BREAST CANCER
Abdel-Qadir, H.
Fischer, H.
Fu, L.
Amir, E.
Harvey, P.
Lee, D. S.
Rochon, P.
Anderson, G.
CANADIAN JOURNAL OF CARDIOLOGY, 2013, 29 (10) : S348 - S348
[48] The Quality of Decisions about Adjuvant Chemotherapy for Early Stage Breast Cancer
Lee, C. N.
Belkora, J.
Wetschler, M.
Chang, Y.
Feibelmann, S.
Moy, B.
Partridge, A.
Sepucha, K.
CANCER RESEARCH, 2009, 69 (24) : 619S - 620S
[49] Osteoporosis after adjuvant treatment for early-stage breast cancer
Christensen, Carina Orts
Jensen, Maj-Britt
Hermann, Anne Pernille
Ewertz, Marianne
DANISH MEDICAL JOURNAL, 2020, 67 (11):
[50] Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer
Philippe L. Bedard
Angelo Di Leo
Martine J. Piccart-Gebhart
Nature Reviews Clinical Oncology, 2010, 7 : 22 - 36

← 1 2 3 4 5 →